Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 1 | Journal of Translational Medicine

Figure 1

From: Autologous mesenchymal stem cell therapy for progressive supranuclear palsy: translation into a phase I controlled, randomized clinical study

Figure 1

Pre-clinical data. Bone marrow mesenchymal stem cells from patients affected by progressive supranuclear palsy have the typical spindle-shaped morphology (A), are positive for mesenchymal-specific antigens to an extended flow-cytometric analysis (B) and express BDNF and GDNF as those from healthy subjects, as demonstrated by real time PCR (C) and ELISA (D). BM MSC: bone marrow mesenchymal stem cells; PSP: Progressive Supranuclear Palsy; HS: healthy subjects. The results of flow cytometric analysis, Elisa and PCR are expressed as mean (±SD).

Back to article page